Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience’s recent animal study reveals promising 12-week results for its DehydraTECH-liraglutide and select CBD formulations in enhancing weight loss, outperforming traditional GLP-1 drugs like semaglutide. The study, which focused on drug delivery innovations, showed accelerated weight loss in the final weeks, highlighting the potential of Lexaria’s technology in diabetes treatment.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.